Currently, immunotherapies for RCC patients include antibodies directed against checkpoint inhibitors, e.g. CTLA-4, PD-1 or PD-L1, the application of bispecific antibodies or chimeric antigen receptors in combination with NK or T cell transfer into the patient [44–46]. The gene discussed is CTLA4; the disease is renal cell carcinoma.